AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
58actual
Sites
4
Countries
Netherlands, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2007-03-08 | actual | When the study began enrolling |
| Primary completion | 2008-06-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-26 | estimated | The whole study's end, after follow-up |
| First posted | 2007-04-20 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Tumor
- Cancer
Intervention
- Drug: AZD6244 — also filed as ARRY-142886
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Part A and Part B
measured Day 1 through 11.8 months (maximum observed duration)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Part A and Part B
measured Day 1 through 11.8 months (maximum observed duration)
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A and Part B
measured Day 1 through 11.8 months (maximum observed duration)
Number of Participants With Abnormal Echocardiogram (ECHO) Parameters Reported as TEAEs in Part A and Part B
measured Day 1 through 11.8 months (maximum observed duration)
Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Part A and Part B
measured Day 1 through 11.8 months (maximum observed duration)
Publications
- PMID 22293660 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed